Alendronate are used as the first line of pharmacological treatment for osteoporosis; however, some of them do not respond adequately to therapy with alendronate. The aim of this study was to investigate the influence of combinations of potential risk alleles (genetic profiles) associated with the response to antiosteoporotic treatment in a cohort consisting of 82 postmenopausal women with primary osteoporosis receiving alendronate (70 mg administered orally per week) for one year. Bone mineral density (BMD; g/cm2) of the femoral neck and lumbar spine was measured. According to BMD change patients were divided in two groups: responders and non-responders to alendronate therapy. Polymorphic variants in CYP19, ER, IL-6, PTHR1, TGFβ, OPG and RANKL genes were determined and profiles generating from the combination of risk alleles. Results: 56 subjects were responders to alendronate and 26 subjects were non-responders. The carriers of A-C-T-C profile (constructed from rs700518, rs1800795, rs2073618, and rs3102735) were predisposed to response to alendronate treatment (P= 0.001). Our findings highlight the importance of identified profiles for pharmacogenetics of alendronate therapy in osteoporosis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.